MRI for the Assessment of Myocardial Viability

Cardiology Clinics

Volumn 25, Issue 1, 2007, Pages 35-56

  Weinsaft, Jonathan W ^a   Klem, Igor ^b   Judd, Robert M ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; AMMONIA N 13; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM;

CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT TOOL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TEST; FABRY DISEASE; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REVASCULARIZATION; HISTOPATHOLOGY; HUMAN; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MORTALITY; MYOCARDIAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

ANIMALS; ARRHYTHMIA; ECHOCARDIOGRAPHY, STRESS; HEART FAILURE, CONGESTIVE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MYOCARDIAL ISCHEMIA; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34247496375     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.02.001     Document Type: Review

References (138)

1. Arnese M., Cornel J.H., Salustri A., et al. Prediction of improvement of regional left ventricular function after surgical revascularization. A comparison of low-dose dobutamine echocardiography with 201Tl single-photon emission computed tomography. Circulation 91 (1995) 2748-2752
2. Ragosta M., Beller G.A., Watson D.D., et al. Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 87 (1993) 1630-1641
3. Dilsizian V., Rocco T.P., Freedman N.M., et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 323 (1990) 141-146
4. Tillisch J., Brunken R., Marshall R., et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 314 (1986) 884-888
5. Braunwald E., and Rutherford J.D. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium.". J Am Coll Cardiol 8 (1986) 1467-1470
6. Rahimtoola S.H. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 72 (1985) V123-V135
7. Chaudhry F.A., Tauke J.T., Alessandrini R.S., et al. Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 34 (1999) 730-738
8. Di Carli M.F., Maddahi J., Rokhsar S., et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 116 (1998) 997-1004
9. Haas F., Haehnel C.J., Picker W., et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 30 (1997) 1693-1700
10. Pagley P.R., Beller G.A., Watson D.D., et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 96 (1997) 793-800
11. Allman K.C., Shaw L.J., Hachamovitch R., et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39 (2002) 1151-1158
12. Wetstein L., Mark R., Kaplinsky E., et al. Histopathologic factors conducive to experimental ventricular tachycardia. Surgery 98 (1985) 532-539
13. Wilber D.J., Lynch J.J., Montgomery D., et al. Postinfarction sudden death: significance of inducible ventricular tachycardia and infarct size in a conscious canine model. Am Heart J 109 (1985) 8-18
14. Josephson M.E., Zimetbaum P., Huang D., et al. Pathophysiologic substrate for sustained ventricular tachycardia in coronary artery disease. Jpn Circ J 61 (1997) 459-466
15. Bolli R. Myocardial 'stunning' in man. Circulation 86 (1992) 1671-1691
16. Vanoverschelde J.L., Wijns W., Depre C., et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 87 (1993) 1513-1523
17. Buxton D.B. Dysfunction in collateral-dependent myocardium. Hibernation or repetitive stunning?. Circulation 87 (1993) 1756-1758
18. Kaul S. Assessing the myocardium after attempted reperfusion: should we bother?. Circulation 98 (1998) 625-627
19. Kim H.W., Wu E., Meyers S.N., et al. Prognosticsignificance of unrecognized myocardial infarction detected by contrast MRI. Circulation 106 supplement 2 (2002) 389
20. Moon J.C., De Arenaza D.P., Elkington A.G., et al. The pathologic basis of Q-wave and non-Q-wave myocardial infarction: a cardiovascular magnetic resonance study. J Am Coll Cardiol 44 (2004) 554-560
21. Fishbein MC, Meerbaum S, Rit J, et al. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981;101:593-600.
22. Dakik H.A., Howell J.F., Lawrie G.M., et al. Assessment of myocardial viability with 99mTc-sestamibi tomography before coronary bypass graft surgery: correlation with histopathology and postoperative improvement in cardiac function. Circulation 96 (1997) 2892-2898
23. Haas F., Augustin N., Holper K., et al. Time course and extent of improvement of dysfunctioning myocardium in patients with coronary artery disease and severely depressed left ventricular function after revascularization: correlation with positron emission tomographic findings. J Am Coll Cardiol 36 (2000) 1927-1934
24. Pohost G.M. Is 31P-NMR spectroscopic imaging a viable approach to assess myocardial viability?. Circulation 92 (1995) 9-10
25. Rehr R.B., Tatum J.L., Hirsch J.I., et al. Reperfused-viable and reperfused-infarcted myocardium: differentiation with in vivo P-31 MR spectroscopy. Radiology 172 (1989) 53-58
26. Rehr R.B., Fuhs B.E., Lee F., et al. Differentiation of reperfused-viable (stunned) from reperfused-infarcted myocardium at 1 to 3 days postreperfusion by in vivo phosphorus-31 nuclear magnetic resonance spectroscopy. Am Heart J 122 (1991) 1571-1582
27. Wroblewski L.C., Aisen A.M., Swanson S.D., et al. Evaluation of myocardial viability following ischemic and reperfusion injury using phosphorus 31 nuclear magnetic resonance spectroscopy in vivo. Am Heart J 120 (1990) 31-39
28. Yabe T., Mitsunami K., Inubushi T., et al. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation 92 (1995) 15-23
29. Bottomley P.A., and Weiss R.G. Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 351 (1998) 714-718
30. Cannon P.J., Maudsley A.A., Hilal S.K., et al. Sodium nuclear magnetic resonance imaging of myocardial tissue of dogs after coronary artery occlusion and reperfusion. J Am Coll Cardiol 7 (1986) 573-579
31. Kim R.J., Lima J.A., Chen E.L., et al. Fast 23Na magnetic resonance imaging of acute reperfused myocardial infarction. Potential to assess myocardial viability. Circulation 95 (1997) 1877-1885
32. Kim R.J., Judd R.M., Chen E.L., et al. Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. Circulation 100 (1999) 185-192
33. Hillenbrand H.B., Becker L.C., Kharrazian R., et al. 23Na MRI combined with contrast-enhanced 1H MRI provides in vivo characterization of infarct healing. Magn Reson Med 53 (2005) 843-850
34. Fieno D.S., Kim R.J., Rehwald W.G., et al. Physiological basis for potassium (39K) magnetic resonance imaging of the heart. Circ Res 84 (1999) 913-920
35. Kim R.J., Hillenbrand H.B., and Judd R.M. Evaluation of myocardial viability by MRI. Herz 25 (2000) 417-430
36. Been M., Smith M.A., Ridgway J.P., et al. Serial changes in the T1 magnetic relaxation parameter after myocardial infarction in man. Br Heart J 59 (1988) 1-8
37. Johnston D.L., Homma S., Liu P., et al. Serial changes in nuclear magnetic resonance relaxation times after myocardial infarction in the rabbit: relationship to water content, severity of ischemia, and histopathology over a six-month period. Magn Reson Med 8 (1988) 363-379
38. Higgins C.B., Herfkens R., Lipton M.J., et al. Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol 52 (1983) 184-188
39. Baer F.M., Theissen P., Schneider C.A., et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 31 (1998) 1040-1048
40. Cwajg J.M., Cwajg E., Nagueh S.F., et al. End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation: relation to rest-redistribution Tl-201 tomography and dobutamine stress echocardiography. J Am Coll Cardiol 35 (2000) 1152-1161
41. Haendchen R.V., Corday E., Torres M., et al. Increased regional end-diastolic wall thickness early after reperfusion: a sign of irreversibly damaged myocardium. J Am Coll Cardiol 3 (1984) 1444-1453
42. Perrone-Filardi P., Bacharach S.L., Dilsizian V., et al. Metabolic evidence of viable myocardium in regions with reduced wall thickness and absent wall thickening in patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 20 (1992) 161-168
43. James O., Kim H.W., Weinsaft J., et al. Demonstration and prediction of the potential reversible nature of thinned myocardium by CMR. J Cardiovasc Magn Reson 7 1 (2005) 69
44. Wellnhoffer E., Olariu A., Klein C., et al. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 109 (2004) 2172-2174
45. Dendale P.A., Franken P.R., Waldman G.J., et al. Low-dosage dobutamine magnetic resonance imaging as an alternative to echocardiography in the detection of viable myocardium after acute infarction. Am Heart J 130 (1995) 134-140
46. Gunning M.G., Anagnostopoulos C., Knight C.J., et al. Comparison of 201Tl, 99mTc-tetrofosmin, and dobutamine magnetic resonance imaging for identifying hibernating myocardium. Circulation 98 (1998) 1869-1874
47. Sandstede J.J., Bertsch G., Beer M., et al. Detection of myocardial viability by low-dose dobutamine Cine MR imaging. Magn Reson Imaging 17 (1999) 1437-1443
48. Sansoy V., Glover D.K., Watson D.D., et al. Comparison of thallium-201 resting redistribution with technetium-99m-sestamibi uptake and functional response to dobutamine for assessment of myocardial viability. Circulation 92 (1995) 994-1004
49. Rehr R.B., Peshock R.M., Malloy C.R., et al. Improved in vivo magnetic resonance imaging of acute myocardial infarction after intravenous paramagnetic contrast agent administration. Am J Cardiol 57 (1986) 864-868
50. McNamara M.T., Tscholakoff D., Revel D., et al. Differentiation of reversible and irreversible myocardial injury by MR imaging with and without gadolinium-DTPA. Radiology 158 (1986) 765-769
51. Eichstaedt H.W., Felix R., Dougherty F.C., et al. Magnetic resonance imaging (MRI) in different stages of myocardial infarction using the contrast agent gadolinium-DTPA. Clin Cardiol 9 (1986) 527-535
52. Baer F.M., Theissen P., Schneider C.A., et al. Magnetic resonance tomography imaging techniques for diagnosing myocardial vitality [German]. Herz 19 (1994) 51-64
53. Saeed M., Wendland M.F., Takehara Y., et al. Reperfusion and irreversible myocardial injury: identification with a nonionic MR imaging contrast medium. Radiology 182 (1992) 675-683
54. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100 (1999) 1992-2002
55. Simonetti O.P., Kim R.J., Fieno D.S., et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218 (2001) 215-223
56. Wagner A., Mahrholdt H., Holly T.A., et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 361 (2003) 374-379
57. Wu E., Judd R.M., Vargas J.D., et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357 (2001) 21-28
58. Ricciardi M.J., Wu E., Davidson C.J., et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 103 (2001) 2780-2783
59. Schaefer S., Malloy C.R., Katz J., et al. Gadolinium-DTPA-enhanced nuclear magnetic resonance imaging of reperfused myocardium: identification of the myocardial bed at risk. J Am Coll Cardiol 12 (1988) 1064-1072
60. Rehwald W.G., Fieno D.S., Chen E.L., et al. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 105 (2002) 224-229
61. Weinmann H.J., Brasch R.C., Press W.R., et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 142 (1984) 619-624
62. Koenig S.H., Spiller M., Brown III R.D., et al. Relaxation of water protons in the intra- and extracellular regions of blood containing Gd(DTPA). Magn Reson Med 3 (1986) 791-795
63. Reimer K.A., and Jennings R.B. Myocardial ischemia, hypoxia and infarction. In: Fozzard H.A., Haber E., Jennings R.B., et al. (Eds). The heart and cardiovascular system (1992), Raven Press, New York 1875-1973
64. Jennings R.B., Schaper J., Hill M.L., et al. Effect of reperfusion late in the phase of reversible ischemic injury. Changes in cell volume, electrolytes, metabolites, and ultrastructure. Circ Res 56 (1985) 262-278
65. Whalen Jr. D.A., Hamilton D.G., Ganote C.E., et al. Effect of a transient period of ischemia on myocardial cells. I. Effects on cell volume regulation. Am J Pathol 74 (1974) 381-397
66. McCormick R.J., Musch T.I., Bergman B.C., et al. Regional differences in LV collagen accumulation and mature cross-linking after myocardial infarction in rats. Am J Physiol 266 (1994) H354-H359
67. Jugdutt B.I., Joljart M.J., and Khan M.I. Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models. Circulation 94 (1996) 94-101
68. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 (2004) 2260-2264
69. Fieno D.S., Kim R.J., Chen E.L., et al. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 36 (2000) 1985-1991
70. Barkhausen J., Ebert W., Debatin J.F., et al. Imaging of myocardial infarction: comparison of magnevist and gadophrin-3 in rabbits. J Am Coll Cardiol 39 (2002) 1392-1398
71. Amado L.C., Gerber B.L., Gupta S.N., et al. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. J Am Coll Cardiol 44 (2004) 2383-2389
72. Mahrholdt H., Wagner A., Holly T.A., et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 106 (2002) 2322-2327
73. Wagner A., Mahrholdt H., Thomson L., et al. Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 47 (2006) 2027-2033
74. Christian T.F., Gibbons R.J., and Gersh B.J. Effect of infarct location on myocardial salvage assessed by technetium-99m isonitrile. J Am Coll Cardiol 17 (1991) 1303-1308
75. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1 (1986) 397-402
76. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. J Am Coll Cardiol 12 (1988) 3A-13A
77. Grines C.L., Browne K.F., Marco J., et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 328 (1993) 673-679
78. Zijlstra F., de Boer M.J., Hoorntje J.C., et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 328 (1993) 680-684
79. Choi K.M., Kim R.J., Gubernikoff G., et al. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation 104 (2001) 1101-1107
80. Tarantini G., Razzolini R., Cacciavillani L., et al. Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty. Am J Cardiol 98 (2006) 1033-1040
81. Beek A.M., Kuhl H.P., Bondarenko O., et al. Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol 42 (2003) 895-901
82. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 (2000) 1445-1453
83. Schvartzman P.R., Srichai M.B., Grimm R.A., et al. Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction. Am Heart J 146 (2003) 535-541
84. Bonow R.O. Identification of viable myocardium. Circulation 94 (1996) 2674-2680
85. Bello D., Shah D.J., Farah G.M., et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 108 (2003) 1945-1953
86. Kim R.J., and Shah D.J. Fundamental concepts in myocardial viability assessment revisited: when knowing how much is "alive" is not enough. Heart 90 (2004) 137-140
87. Gerber B.L., Garot J., Bluemke D.A., et al. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 106 (2002) 1083-1089
88. Hombach V., Grebe O., Merkle N., et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 26 (2005) 549-557
89. Vanoverschelde J.L., D'Hondt A.M., Marwick T., et al. Head-to-head comparison of exercise-redistribution-reinjection thallium single-photon emission computed tomography and low dose dobutamine echocardiography for prediction of reversibility of chronic left ventricular ischemic dysfunction. J Am Coll Cardiol 28 (1996) 432-442
90. Perrone-Filardi P., Pace L., Prastaro M., et al. Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography. Circulation 94 (1996) 2712-2719
91. Bax J.J., Wijns W., Cornel J.H., et al. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 30 (1997) 1451-1460
92. Nelson C., McCrohon J., Khafagi F., et al. Impact of scar thickness on the assessment of viability using dobutamine echocardiography and thallium single-photon emission computed tomography: a comparison with contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 43 (2004) 1248-1256
93. Thiele H., Nagel E., Paetsch I., et al. Functional cardiac MR imaging with steady-state free precession (SSFP) significantly improves endocardial border delineation without contrast agents. J Magn Reson Imaging 14 (2001) 362-367
94. Grothues F., Smith G.C., Moon J.C., et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90 (2002) 29-34
95. Kim R.J., and Manning W.J. Viability assessment by delayed enhancement cardiovascular magnetic resonance: will low-dose dobutamine dull the shine?. Circulation 109 (2004) 2476-2479
96. Klein C., Nekolla S.G., Bengel F.M., et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 105 (2002) 162-167
97. Kuhl H.P., Beek A.M., van der Weerdt A.P., et al. Myocardial viability in chronic ischemic heart disease: comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 41 (2003) 1341-1348
98. Lee V.S., Resnick D., Tiu S.S., et al. MR imaging evaluation of myocardial viability in the setting of equivocal SPECT results with (99m)Tc sestamibi. Radiology 230 (2004) 191-197
99. Kitagawa K., Sakuma H., Hirano T., et al. Acute myocardial infarction: myocardial viability assessment in patients early thereafter comparison of contrast-enhanced MR imaging with resting (201)Tl SPECT. Single photon emission computed tomography. Radiology 226 (2003) 138-144
100. Baks T., Cademartiri F., Moelker A.D., et al. Multislice computed tomography and magnetic resonance imaging for the assessment of reperfused acute myocardial infarction. J Am Coll Cardiol 48 (2006) 144-152
101. Mahnken A.H., Koos R., Katoh M., et al. Assessment of myocardial viability in reperfused acute myocardial infarction using 16-slice computed tomography in comparison to magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 2042-2047
102. Lardo A.C., Cordeiro M.A., Silva C., et al. Contrast-enhanced multidetector computed tomography viability imaging after myocardial infarction: characterization of myocyte death, microvascular obstruction, and chronic scar. Circulation 113 (2006) 394-404
103. Felker G.M., Shaw L.K., and O'Connor C.M. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 39 (2002) 210-218
104. Uretsky B.F., Thygesen K., Armstrong P.W., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. Circulation 102 (2000) 611-616
105. Roberts W.C., Siegel R.J., and McManus B.M. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 60 (1987) 1340-1355
106. Kubo N., Morimoto S., Hiramitsu S., et al. Feasibility of diagnosing chronic myocarditis by endomyocardial biopsy. Heart Vessels 12 (1997) 167-170
107. McCrohon J.A., Moon J.C., Prasad S.K., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 (2003) 54-59
108. Patel MR, Heitner JF, Klem I. Presence and pattern of scar on delayed-enhancement MRI differentiates ischemic from non-ischemic cardiomyopathy. Circulation 2004;108(Suppl):755.
109. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 (2000) 1077-1084
110. Kyle R.A., Gertz M.A., Greipp P.R., et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336 (1997) 1202-1207
111. Mahrholdt H., Wagner A., Deluigi C.C., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114 (2006) 1581-1590
112. Mahrholdt H., Goedecke C., Wagner A., et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109 (2004) 1250-1258
113. Patel M.R., Cawley P.J., Heitner J.F., et al. Delayed enhancement MRI improves the ability to detect cardiac involvement in patients with sarcoidosis. Circulation 110 (2004) II-645
114. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 (2005) 1683-1690
115. Schulz-Menger J., Wassmuth R., Abdel-Aty H., et al. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart 92 (2006) 399-400
116. Maceira A.M., Joshi J., Prasad S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 (2005) 186-193
117. Rochitte C.E., Oliveira P.F., Andrade J.M., et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol 46 (2005) 1553-1558
118. Moon J.C., McKenna W.J., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1567
119. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 (2002) 2156-2164
120. Beer M., Weidemann F., Breunig F., et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 97 (2006) 1515-1518
121. Weidemann F., Breunig F., Beer M., et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26 (2005) 1221-1227
122. Moon J.C., Sachdev B., Elkington A.G., et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 (2003) 2151-2155
123. Basso C., Thiene G., Corrado D., et al. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31 (2000) 988-998
124. Maron B.J., Epstein S.E., and Roberts W.C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 43 (1979) 1086-1102
125. Varnava A.M., Elliott P.M., Sharma S., et al. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 84 (2000) 476-482
126. Tanaka M., Fujiwara H., Onodera T., et al. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 55 (1986) 575-581
127. Mahrholdt H., Choudhury L., Wagner A., et al. Relation of myocardial scarring to clinical risk factors for sudden cardiac death in hypertrophic cardiomyopathy. Circulation 106 (2002) II-652
128. Gradel C., Jain D., Batsford W.P., et al. Relationship of scar and ischemia to the results of programmed electrophysiological stimulation in patients with coronary artery disease. J Nucl Cardiol 4 (1997) 379-386
129. Buxton A.E., Hafley G.E., Lehmann M.H., et al. Prediction of sustained ventricular tachycardia inducible by programmed stimulation in patients with coronary artery disease. Utility of clinical variables. Circulation 99 (1999) 1843-1850
130. De Sutter J., Tavernier R., Van de Wiele C., et al. Infarct size and recurrence of ventricular arrhythmias after defibrillator implantation. Eur J Nucl Med 27 (2000) 807-815
131. van der Burg A., Bax J.J., Boersma E., et al. Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden death. Circulation 108 (2003) 1954-1959
132. Gioia G., Bagheri B., Gottlieb C.D., et al. Prediction of outcome of patients with life-threatening ventricular arrhythmias treated with automatic implantable cardioverter-defibrillators using SPECT perfusion imaging. Circulation 95 (1997) 390-394
133. Wetstein L., Mark R., Kaplinsky E., et al. Histopathologic correlates of inducible ventricular tachycardia in two experimental canine models of myocardial infarction. Am J Med Sci 291 (1986) 222-231
134. Bello D., Fieno D.S., Kim R.J., et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 45 (2005) 1104-1108
135. Klem I., Weinsaft J., Heitner J.F., et al. The utility of contrast enhanced MRI for screening patients at risk for malignant ventricular tachyarrhythmias. J Cardiovasc Magn Reson 6 (2004) 84
136. Nazarian S., Bluemke D.A., Lardo A.C., et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in non-ischemic cardiomyopathy. Circulation 112 (2005) 2821-2825
137. Kwong R.Y., Chan A., Brown K., et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 113 (2006) 2733-2743
138. Yan A.T., Shayne A.J., Brown K.A., et al. Characterization of the per-infarct zone by contrast-enhanced magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 114 (2006) 32-39